TRPV4 and endothelial dysfunction: Furthermore, compounds such as Thonningianin A and Carfilzomib effectively protect against endothelial dysfunction and impaired vasodilation by restoring the GPR35‐TRPV4 interaction, suggesting a new precise therapeutic strategy for preventing vasodilation impairment in aging arteries.